Kymera's top drug hunter leaves for Alexis Borisy's Curie.Bio; What’s done is Dunn: FDA neuroscience leader bows out
By day two of his job as CSO partner at Alexis Borisy’s new investment and biotech services firm, Chris De Savi had already gone through the due diligence with multiple founders looking to get their ideas off the ground and into the experimentation phase.
The former Kymera Therapeutics drug discovery leader joined Curie.Bio this week to prop up new biotech founders and provide expertise to get their science and tech up to snuff. He’s the first of what will likely be about half a dozen CSO partners to be hired at Curie this year as the company looks to build out a 50- to 60-person team that helps early-stage entrepreneurs turn their ideas into 12- to 24-month experimental plans that can get them to data that will woo Series A investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.